Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B

Open source

DOI: 10.1136/jitc-2024-010674
Published: 2025 Feb 4
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2024-010674,
  title = {Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50\% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.},
  author = {Cortellini A and Brunetti L and Di Fazio GR and Garbo E and Pinato DJ and Naidoo J and Katz A and Loza M and Neal JW and Genova C and Gettinger S and Kim SY and Jayakrishnan R and El Zarif T and Russano M and Pecci F and Di Federico A and Awad M and Alessi JV and Montrone M and Owen DH and Signorelli D and Fidler MJ and Li M and Camerini A and De Giglio A and Young L and Vincenzi B and Metro G and Passiglia F and Yendamuri S and Guida A and Ghidini M and Awosika NO and Napolitano A and Fulgenzi CAM and Grisanti S and Grossi F and D'Incecco A and Josephides E and Van Hemelrijck M and Russo A and Gelibter A and Spinelli G and Verrico M and Tomasik B and Giusti R and Newsom-Davis T and Bria E and Sebastian M and Rost M and Forster M and Mukherjee U and Landi L and Mazzoni F and Aujayeb A and Dupont M and Curioni-Fontecedro A and Chiari R and Pantano F and Morabito A and Leonetti A and Friedlaender A and Addeo A and Zoratto F and De Tursi M and Cantini L and Roca E and Mountzios G and Della Gravara L and Kalvapudi S and Inno A and Bironzo P and Di Marco Barros R and O'Reilly D and Bell J and Karapanagiotou E and Monnet I and Baena J and Macerelli M and Majem M and Agustoni F and Cortinovis DL and Tonini G and Minuti G and Bennati C and Mezquita L and Gorría T and Servetto A and Beninato T and Lo Russo G and Rogado J and Moliner L and Biello F and Aboubakar Nana F and Dingemans AM and Aerts JGJV and Ferrara R and Torri V and Hejleh TA and Takada K and Naqash AR and Garassino M and Peters S and Wakelee H and Nassar AH and Ricciuti B},
  year = {2025},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2024-010674},
  url = {https://doi.org/10.1136/jitc-2024-010674}
}

RIS

TY  - JOUR
TI  - Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
AU  - Cortellini A
AU  - Brunetti L
AU  - Di Fazio GR
AU  - Garbo E
AU  - Pinato DJ
AU  - Naidoo J
AU  - Katz A
AU  - Loza M
AU  - Neal JW
AU  - Genova C
AU  - Gettinger S
AU  - Kim SY
AU  - Jayakrishnan R
AU  - El Zarif T
AU  - Russano M
AU  - Pecci F
AU  - Di Federico A
AU  - Awad M
AU  - Alessi JV
AU  - Montrone M
AU  - Owen DH
AU  - Signorelli D
AU  - Fidler MJ
AU  - Li M
AU  - Camerini A
AU  - De Giglio A
AU  - Young L
AU  - Vincenzi B
AU  - Metro G
AU  - Passiglia F
AU  - Yendamuri S
AU  - Guida A
AU  - Ghidini M
AU  - Awosika NO
AU  - Napolitano A
AU  - Fulgenzi CAM
AU  - Grisanti S
AU  - Grossi F
AU  - D'Incecco A
AU  - Josephides E
AU  - Van Hemelrijck M
AU  - Russo A
AU  - Gelibter A
AU  - Spinelli G
AU  - Verrico M
AU  - Tomasik B
AU  - Giusti R
AU  - Newsom-Davis T
AU  - Bria E
AU  - Sebastian M
AU  - Rost M
AU  - Forster M
AU  - Mukherjee U
AU  - Landi L
AU  - Mazzoni F
AU  - Aujayeb A
AU  - Dupont M
AU  - Curioni-Fontecedro A
AU  - Chiari R
AU  - Pantano F
AU  - Morabito A
AU  - Leonetti A
AU  - Friedlaender A
AU  - Addeo A
AU  - Zoratto F
AU  - De Tursi M
AU  - Cantini L
AU  - Roca E
AU  - Mountzios G
AU  - Della Gravara L
AU  - Kalvapudi S
AU  - Inno A
AU  - Bironzo P
AU  - Di Marco Barros R
AU  - O'Reilly D
AU  - Bell J
AU  - Karapanagiotou E
AU  - Monnet I
AU  - Baena J
AU  - Macerelli M
AU  - Majem M
AU  - Agustoni F
AU  - Cortinovis DL
AU  - Tonini G
AU  - Minuti G
AU  - Bennati C
AU  - Mezquita L
AU  - Gorría T
AU  - Servetto A
AU  - Beninato T
AU  - Lo Russo G
AU  - Rogado J
AU  - Moliner L
AU  - Biello F
AU  - Aboubakar Nana F
AU  - Dingemans AM
AU  - Aerts JGJV
AU  - Ferrara R
AU  - Torri V
AU  - Hejleh TA
AU  - Takada K
AU  - Naqash AR
AU  - Garassino M
AU  - Peters S
AU  - Wakelee H
AU  - Nassar AH
AU  - Ricciuti B
PY  - 2025
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2024-010674
UR  - https://doi.org/10.1136/jitc-2024-010674
ER  -

APA

A, C., L, B., GR, D. F., E, G., DJ, P., J, N., A, K., M, L., JW, N., C, G., S, G., SY, K., R, J., T, E. Z., M, R., F, P., A, D. F., M, A., JV, A., M, M., DH, O., D, S., MJ, F., M, L., A, C., A, D. G., L, Y., B, V., G, M., F, P., S, Y., A, G., M, G., NO, A., A, N., CAM, F., S, G., F, G., A, D., E, J., M, V. H., A, R., A, G., G, S., M, V., B, T., R, G., T, N., E, B., M, S., M, R., M, F., U, M., L, L., F, M., A, A., M, D., A, C., R, C., F, P., A, M., A, L., A, F., A, A., F, Z., M, D. T., L, C., E, R., G, M., L, D. G., S, K., A, I., P, B., R, D. M. B., D, O., J, B., E, K., I, M., J, B., M, M., M, M., F, A., DL, C., G, T., G, M., C, B., L, M., T, G., A, S., T, B., G, L. R., J, R., L, M., F, B., F, A. N., AM, D., JGJV, A., R, F., V, T., TA, H., K, T., AR, N., M, G., S, P., H, W., AH, N., & B, R. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2024-010674

Source records

pubmed · retrieved 2026-09-27T14:38:10.979Z